Opioid Addiction Treatment: MAT, Therapy & Recovery

Opioid addiction is diagnosed using the DSM-5 criteria for opioid use disorder — at least 2 of the following 11 criteria within the same 12-month period, with severity classified as mild (2–3 criteria), moderate (4–5), or severe (6+). Recognizing these signs — in yourself or someone you care about — is the first step toward getting the appropriate level of help:

• Taking opioids in larger amounts or for longer than intended — starting a prescription at a therapeutic dose and finding that the amount needed escalates, or using for longer than the clinical scenario warrants
• Persistent desire or unsuccessful efforts to cut down or control opioid use — repeated attempts to stop or reduce, followed by return to prior use levels
• Spending significant time obtaining, using, or recovering from opioids — hours each day dedicated to procurement, use, and recovery from effects; daily functioning is reorganized around opioid use
• Craving — an intense urge or desire to use opioids, particularly in contexts previously associated with use
• Failure to fulfill major role obligations — job performance decline, missed work, neglected parenting responsibilities, academic failure
• Continued use despite social or interpersonal problems caused or worsened by opioids — relationship conflicts about use that do not lead to cessation
• Giving up important activities — abandoning hobbies, social relationships, or professional activities that were previously important
• Using in hazardous situations — driving while impaired, using in occupational settings where impairment creates safety risk
• Continuing use despite physical or psychological harm — using despite an opioid-related medical condition, worsening depression or anxiety, or direct clinical advice to stop
• Tolerance — requiring substantially more opioids to achieve the same effect, or noticeably diminished effect with the same dose
• Withdrawal — experiencing opioid withdrawal symptoms when not using, or using opioids to prevent withdrawal

Behavioral signs of opioid addiction — beyond the DSM-5 criteria — include "prescription shopping" (visiting multiple prescribers to obtain opioids), purchasing opioids illicitly, concealing use from family members or employers, progressive financial problems related to drug costs, and withdrawal from previously enjoyed social activities.

Physical signs during active opioid use include pinpoint (miotic) pupils, drowsiness and "nodding" (sedated head-drooping), slowed or shallow breathing (respiratory depression), constipation, itching, and — in individuals who inject — track marks or venous scarring at injection sites. Physical signs progress with dose escalation and can include significant weight loss and pronounced functional decline.

Overdose recognition is life-saving knowledge. Signs of opioid overdose include unresponsiveness to stimulation, cyanosis (blue lips, fingernails, or skin), extremely slow, shallow, or absent breathing, and gurgling or snoring sounds. If you observe these signs, administer naloxone (Narcan) immediately if available, call 911, and do not leave the person alone. Florida's Good Samaritan Law provides immunity from prosecution for individuals who call 911 to report an overdose.

Confidential same-day clinical assessments are available at DCF-licensed PHP and IOP programs. Verify insurance coverage or visit the admissions page to begin.

The opioid class includes dozens of compounds across three chemical categories — natural, semi-synthetic, and synthetic — each with different potency, onset, duration, and overdose risk profiles, but all sharing the common mechanism of mu-opioid receptor agonism that drives addiction and respiratory depression in overdose. Understanding the opioid landscape matters for treatment, because the type of opioid used affects withdrawal timing, MOUD dosing considerations, and overdose risk from relapse.

Natural opioids are derived directly from the opium poppy (Papaver somniferum). Morphine is the prototypical natural opioid — the pharmacological standard against which all other opioids are measured in morphine milligram equivalents (MME). Codeine, also a natural opioid, is found in cough preparations and combination analgesics and is often the first opioid encountered in misuse, despite a relatively low addiction liability compared to more potent opioids.

Semi-synthetic opioids are chemically derived from natural opioid precursors. Oxycodone (Percocet, OxyContin), hydrocodone (Vicodin), oxymorphone, and heroin fall into this category. Oxycodone and hydrocodone drove the first wave of the opioid crisis — the aggressive prescribing of extended-release oxycodone formulations in the late 1990s and 2000s, combined with misleading pharmaceutical marketing minimizing addiction risk, seeded widespread opioid use disorder across the United States. Heroin, also semi-synthetic, is now rarely a "pure" substance in the U.S. market — laboratory testing consistently identifies fentanyl or fentanyl analogues in samples sold as heroin, dramatically elevating the overdose risk for individuals who believe they are using a substance they are tolerant to.

Synthetic opioids are fully lab-synthesized and represent the most potent and most clinically dangerous category. Fentanyl, 50–100 times more potent than morphine by weight, exists in both pharmaceutical (Duragesic patches, Sublimaze) and illicit forms. Illicit fentanyl — pressed into counterfeit pills that visually resemble Xanax, Percocet, or other medications — is responsible for the third wave of the opioid crisis and accounts for approximately 73% of all opioid overdose deaths in 2023. Tramadol, an atypical synthetic opioid with additional serotonin and norepinephrine reuptake inhibiting properties, has a historically underestimated addiction and overdose risk — including seizure risk in overdose that is not seen with pure opioid agonists.

The three waves of the opioid crisis reflect the evolution of the opioid supply: prescription opioid overdose deaths peaked around 2011; heroin deaths rose from 2010 to 2016 as prescribing declined and individuals with OUD transitioned to a cheaper, more accessible illicit supply; synthetic opioid deaths began rising in 2013 and continue accelerating in 2023, with illicit fentanyl now the dominant driver of overdose mortality. Each wave shaped a different population of people with OUD — and effective treatment must meet each of them where they are, without requiring a single defined "pathway" into opioid use disorder as a prerequisite for compassionate, evidence-based care.

Medication for opioid use disorder (MOUD) — specifically buprenorphine, methadone, and naltrexone — is the evidence-based standard of care for opioid use disorder, endorsed by SAMHSA, ASAM, NIDA, the CDC, and the U.S. Surgeon General as first-line treatment for moderate to severe OUD. The evidence for MOUD is among the strongest in all of addiction medicine: randomized controlled trials, systematic reviews, and real-world outcome data consistently show that MOUD reduces overdose mortality by 50–70%, improves treatment retention, reduces illicit opioid use, and decreases the social and criminal consequences of untreated OUD.

Buprenorphine is a partial opioid agonist — it activates the mu-opioid receptor, eliminating withdrawal and craving, but with a ceiling effect that reduces overdose risk compared to full agonists. It is prescribed in office-based settings (since the DATA 2000 Act removed the requirement for specialized clinic dispensing), meaning any licensed prescriber can provide it in standard outpatient or PHP/IOP programming. The most common formulation is sublingual buprenorphine/naloxone (Suboxone), though extended-release injectable buprenorphine (Sublocade, monthly injection) is increasingly available and removes the daily dosing compliance requirement. Buprenorphine reduces opioid-related overdose mortality by 50–70% and significantly improves treatment retention compared to placebo or behavioral-only treatment. It is the MOUD most accessible through integrated PHP and IOP programming.

Methadone is a full opioid agonist with the highest treatment retention rates in severe OUD — particularly for individuals with long use histories, prior treatment failures, or high-dose opioid use. Because methadone for OUD is dispensed through federally licensed Opioid Treatment Programs (OTPs), it requires daily clinic attendance initially — a barrier for some but a source of structure and accountability for others. PHP and IOP programs refer individuals appropriate for methadone maintenance to licensed OTP partners.

Naltrexone (Vivitrol) is a pure opioid antagonist — it blocks all opioid effects at the receptor level and produces no opioid agonist activity. The extended-release injectable formulation (Vivitrol, monthly injection) is particularly useful for individuals who prefer full opioid blockade, work in safety-sensitive occupations, or are in settings where buprenorphine diversion is a concern. The critical requirement: naltrexone induction requires a minimum 7–14 days of opioid abstinence to prevent precipitated withdrawal. Head-to-head trials show lower retention with naltrexone compared to buprenorphine in community settings, though outcomes in highly motivated patients with supported induction are comparable.

Behavioral therapy as co-treatment with MOUD is associated with better outcomes than MOUD alone — and is required by most commercial insurance plans as a concurrent treatment condition for MOUD coverage. Cognitive-behavioral therapy (CBT), motivational interviewing, contingency management, and process groups delivered in PHP and IOP settings provide the behavioral skill-building and therapeutic support that makes MOUD most effective. The combination of MOUD plus intensive behavioral treatment at the PHP or IOP level represents the evidence-based gold standard for outpatient OUD care. Learn more about medication-assisted treatment.

A note on abstinence-only treatment approaches: programs that refuse MOUD or require individuals to discontinue MOUD as a condition of treatment — including some 12-step-only residential programs and faith-based recovery communities — have substantially worse outcomes in moderate-to-severe OUD and are associated with significantly higher post-discharge overdose mortality. This reflects both the loss of opioid tolerance during treatment and the absence of the mortality-reducing pharmacological protection of MOUD. Evidence-based MOUD-affirming programs do not require discontinuation of clinically indicated medications as a condition of participation.

Opioid withdrawal is medically significant — while rarely directly fatal in otherwise healthy adults, the severity of opioid withdrawal drives the majority of early treatment dropout and is the primary cause of relapse during the acute cessation period, making clinical management of withdrawal the critical first step in opioid addiction treatment.

The COWS (Clinical Opioid Withdrawal Scale) is the clinical instrument used to quantify opioid withdrawal severity: an 11-item assessment scoring items including resting pulse rate, sweating, restlessness, pupil size, bone or joint aches, runny nose, GI symptoms, tremor, yawning, anxiety, and gooseflesh. Scores are interpreted as: less than 5 — no significant withdrawal; 5–12 — mild withdrawal; 13–24 — moderate withdrawal; 25–36 — moderately severe withdrawal; greater than 36 — severe withdrawal. Buprenorphine induction is initiated when the COWS score reaches 8 or higher — initiating buprenorphine before sufficient withdrawal onset risks precipitated withdrawal, an abrupt and severe worsening of withdrawal symptoms caused by buprenorphine displacing full agonist opioids from the receptor at a higher affinity.

The timeline of opioid withdrawal varies by opioid type and half-life. Short-acting opioid withdrawal (heroin, oxycodone, hydrocodone) typically begins 8–24 hours after last use, peaks at 36–72 hours with flu-like symptoms (muscle aches, nausea, vomiting, diarrhea, insomnia, anxiety, diaphoresis, dilated pupils), and largely resolves within 5–7 days without MOUD. Long-acting opioid withdrawal (methadone misuse) has a delayed onset — symptoms may not begin for 36–48 hours — and can persist for 2–3 weeks. Fentanyl withdrawal, despite fentanyl's long tissue half-life, tends to have a faster onset than heroin due to the speed of receptor clearance when fentanyl is no longer being actively dosed. Acute withdrawal in all forms is dramatically shortened and blunted by buprenorphine induction.

Post-acute withdrawal symptoms (PAWS) — including insomnia, anxiety, dysphoria, and episodic cravings — can persist for weeks to months following the acute withdrawal phase in individuals with longer opioid use histories. MOUD effectively suppresses these post-acute symptoms, which is one of the clinical rationales for extended (often indefinite) MOUD rather than time-limited detox-and-stop approaches. For more detail on the full opioid withdrawal timeline, see our dedicated opioid detox timeline guide. If you need help accessing detox before PHP or IOP admission, detox placement coordination is available through ASAM-certified admissions teams.

Level-of-care placement for opioid use disorder treatment is determined by ASAM Criteria assessment across 6 clinical dimensions — and the majority of individuals with OUD who are medically stable are best served by PHP (ASAM Level 2.5) or IOP (ASAM Level 2.1), which provide sufficient clinical intensity for MOUD initiation and behavioral treatment without the costs and disruption of residential care.

The 6 ASAM Dimensions evaluated at intake:

• Dimension 1 — Acute Intoxication and Withdrawal Potential: the most proximate factor in initial placement; active severe opioid withdrawal, polysubstance withdrawal with seizure risk (alcohol, benzodiazepines), or significant medical instability from withdrawal complications may require inpatient medically managed detox before outpatient programming; most individuals with uncomplicated opioid withdrawal can safely begin buprenorphine induction in a PHP or IOP setting
• Dimension 2 — Biomedical Conditions and Complications: opioid-related medical complications (endocarditis, wound infections, hepatitis C, HIV in people who inject drugs) that require concurrent medical management may influence placement toward higher-level care; stable chronic medical conditions are managed concurrently with outpatient OUD treatment
• Dimension 3 — Emotional, Behavioral, and Cognitive Conditions: co-occurring psychiatric disorders (major depression, PTSD, bipolar disorder, anxiety disorders) are extremely common in OUD — 50–70% prevalence — and require concurrent psychiatric treatment; active suicidal ideation with plan or intent may require brief psychiatric hospitalization before PHP admission
• Dimension 4 — Readiness to Change: individuals in precontemplation or ambivalence benefit from motivational interviewing-intensive programming; PHP's daily contact provides maximum motivational engagement; lower-readiness OUD is not a contraindication for PHP but informs the therapeutic approach
• Dimension 5 — Relapse, Continued Use, or Continued Problem Potential: high relapse risk (multiple prior treatment episodes, strong environmental triggers, active opioid cravings) supports PHP over IOP initially; prior overdose history markedly elevates risk and supports the highest appropriate outpatient level of care
• Dimension 6 — Recovery/Living Environment: unstable housing, active use in the home, or high-availability drug environments support PHP with concurrent transition planning to FARR-certified sober living homes

Medically managed intensive inpatient (ASAM Level 4) is rarely required for OUD in isolation — it is indicated for severe medical or psychiatric instability that cannot be managed in less restrictive settings.

Medically managed detox (ASAM Level 3.7) is appropriate for high-dose or polysubstance opioid withdrawal, prior seizure history, or clinical presentations where outpatient buprenorphine induction is not feasible; typically 3–7 days with transition directly to PHP. Detox placement coordination is available for individuals who need detox before stepping into outpatient programming.

PHP (ASAM Level 2.5) — Partial Hospitalization Program — provides MOUD induction and management, daily group and individual therapy, psychiatric services, and case management at 25–35 hours per week, Monday through Friday.

IOP (ASAM Level 2.1) — Intensive Outpatient Program — serves as either a step-down from PHP after stabilization or as a primary level of care for lower-acuity OUD with a stable home environment; 9–15 hours per week with continued MOUD management, group therapy, and prescriber monitoring.

ASAM Criteria assessments and same-day admissions are available at DCF-licensed PHP and IOP programs. Verify insurance coverage to begin level-of-care determination.

Recovery from opioid use disorder is a long-term process — OUD is a chronic, relapsing-remitting condition comparable in its disease trajectory to type 2 diabetes or hypertension — and the clinical goal is not short-term abstinence from both opioids and medication, but sustained functional recovery and reduced risk of the catastrophic consequence of untreated OUD: overdose death.

Long-term MOUD is the clinical recommendation of ASAM and SAMHSA for the majority of individuals with moderate-to-severe OUD. There is no evidence-based timeframe after which MOUD should be discontinued in someone who is stable and benefiting from it — just as there is no defined endpoint for antihypertensive treatment in a patient whose blood pressure is well-controlled. The decision to taper MOUD should always be patient-initiated, developed collaboratively with the prescribing clinician, and implemented gradually with close monitoring for return of cravings or use. The most dangerous moment in MOUD treatment is premature discontinuation — opioid tolerance returns to zero within days of stopping buprenorphine or methadone, meaning a person who relapses has dramatically elevated overdose risk from a previously tolerated dose.

Long-term recovery outcomes with MOUD plus behavioral treatment are meaningfully positive. Five-year follow-up studies show that 40–60% of individuals with OUD achieve sustained remission with MOUD-integrated treatment — compared to typically less than 15% sustained 5-year remission in untreated OUD. These numbers are not causes for pessimism about OUD treatment efficacy; they are causes for sustained clinical engagement. The majority of people who achieve long-term remission do so after multiple treatment episodes — the trajectory of OUD recovery is rarely linear, and early episodes often build the insight and relapse prevention capacity that supports eventual sustained remission.

Relapse as part of recovery: NIDA defines relapse not as treatment failure but as a clinical signal that the current treatment plan needs adjustment — a change in MOUD dose, an increase in behavioral treatment intensity, or an evaluation of untreated co-occurring psychiatric conditions that are fueling use. The 40–60% of individuals with SUD who experience at least one relapse during recovery is evidence of the chronicity of the disease, not evidence of a character deficiency. The clinically critical variable is not whether relapse occurs, but the response to relapse — immediate return to treatment rather than shame-driven avoidance is the single most important determinant of long-term outcomes.

Community and peer support amplify the outcomes achieved through clinical treatment. Narcotics Anonymous (NA) provides a 12-step fellowship model; SMART Recovery offers a non-12-step, CBT-informed peer support framework; medication-friendly recovery communities are growing in visibility and are particularly important for individuals on MOUD who may encounter stigma in traditional 12-step settings. Peer recovery coaches — individuals with lived experience of OUD and recovery who provide community-based support — are an evidence-supported adjunct to clinical care. Alumni programming at evidence-based PHP and IOP programs connects graduates with ongoing peer support in recovery communities.

Overdose mortality in long-term perspective: individuals with OUD who remain on MOUD have 5–8 times lower overdose mortality than those with untreated OUD. Remaining on buprenorphine or methadone is not a sign of weakness, incomplete recovery, or "not really sober" — it is a life-saving medical decision supported by the strongest evidence in addiction medicine. Evidence-based MOUD-affirming programs work actively to counter the harmful stigma that discourages individuals from remaining on clinically indicated medications.

MOUD-integrated PHP and IOP treatment is available at DCF-licensed programs. Verify your insurance or visit the admissions page for confidential assessment and same-day admission support.